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Gemcitabine (GEM, 20,20-diﬂuorodeoxycytidine) is currently used in advanced pancreatic adenocarcinoma, with a response rate
of o 20%. The purpose of our work was to improve GEM activity by addition of cannabinoids. Here, we show that GEM induces
both cannabinoid receptor-1 (CB1) and cannabinoid receptor-2 (CB2) receptors by an NF-jB-dependent mechanism and that its
association with cannabinoids synergistically inhibits pancreatic adenocarcinoma cell growth and increases reactive oxygen
species (ROS) induced by single treatments. The antiproliferative synergism is prevented by the radical scavenger N-acetyl-
L-cysteine and by the speciﬁc NF-jB inhibitor BAY 11-7085, demonstrating that the induction of ROS by GEM/cannabinoids and
of NF-jB by GEM is required for this effect. In addition, we report that neither apoptotic nor cytostatic mechanisms are
responsible for the synergistic cell growth inhibition, which is strictly associated with the enhancement of endoplasmic
reticulum stress and autophagic cell death. Noteworthy, the antiproliferative synergism is stronger in GEM-resistant pancreatic
cancer cell lines compared with GEM-sensitive pancreatic cancer cell lines. The combined treatment strongly inhibits growth of
human pancreatic tumor cells xenografted in nude mice without apparent toxic effects. These ﬁndings support a key role of the
ROS-dependent activation of an autophagic program in the synergistic growth inhibition induced by GEM/cannabinoid
combination in human pancreatic cancer cells.
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Pancreatic adenocarcinoma is one of the most aggressive
and devastating human malignancies with a death-to-
incidence ratio of 0.99. Although it represents only 2–3% of
all cancers, pancreatic adenocarcinoma is the fourth cause
of death by tumors.
1 At diagnosis, o20% of patients are
candidatesforsurgerywithcurativeintent.
2Monotherapy with
gemcitabine (GEM, 20,20-diﬂuorodeoxycytidine) has been the
standard treatment during the last decade for its modest
improvement in the quality of life of patients, although it has a
response rate of o20%.
3 Many clinical trials have failed to
demonstrate an improvement in overall survival with the
addition of different drugs to GEM, including cetuximab and
bevacizumab.
1 Nevertheless, some modest but interesting
advances have been provided by drug combination therapies,
such as GEM–erlotinib, GEM–capecitabine, and GEM–
platinum salt.
2 Nowadays, research is focused on the
identiﬁcation of novel potential targets to efﬁciently enhance
GEM antitumor activity. Reactive oxygen species (ROS) have
recently emerged as promising targets for anticancer drug
discovery. Indeed, constitutively elevated levels of ROS
represent a speciﬁc vulnerability of malignant cells that can
be selectively targeted bypro-oxidant drugs.
4Accordingly, we
have recently demonstrated that the induction of ROS is one
of the mechanisms of GEM antitumor action and that
pancreatic adenocarcinoma cell lines with lower basal levels
of ROS are more resistant to GEM compared with cells with
higher ROS levels.
5
In recent years, there has been increasing interest in
cannabinoids as therapeutic drugs for their antineoplastic,
anticachectic, and analgesic potential. Growth inhibitory
activitiesofcannabinoidshavebeendemonstratedforvarious
malignancies, including brain, breast, prostate, colorectal,
skin and, recently, pancreatic cancer.
6,7 Cannabinoid effects
are mediated through the activation of G-protein-coupled
receptors, namely cannabinoid receptor-1 (CB1)
8 and canna-
binoid receptor-2 (CB2).
9 Noteworthy, these receptors are
overexpressed in several tumors, including pancreatic adeno-
carcinoma,whereas they are undetectableor expressedatlow
level in normal tissues,
10 suggesting that a cannabinoid-based
therapy may activate cell death pathways predominantly in
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www.nature.com/cddistumor cells. A causal relationship between ROS production
and cell death has also been demonstrated in cannabinoid-
induced cell growth inhibition. In this regard, Sarker et al.
11
have shown that the cannabinoid anandamide induces
apoptosis of PC-12 cells by increasing superoxide levels.
Furthermore, it has been observed that cannabinoid admin-
istration in rats induces cerebral lipoperoxidation under
ex vivo conditions.
12 Recent ﬁndings have shown that the
tumor growth-inhibiting activity of cannabinoids relies on the
upregulation of the endoplasmic reticulum (ER) stress path-
way
13 and that ROS enhancement can determine perturba-
tions of ER homeostasis affecting protein folding, thus
causing ER stress.
14 ER stress response involves transla-
tional attenuation, upregulation of ER chaperone genes and
related proteins, and degradation of unfolded proteins by a
quality-control system.
15 The ER resident transmembrane
kinase/endoribonuclease IRE1 (inositol-requiring ER to
nucleus signal kinase 1) is a primary ER sensor for unfolded
proteins.
16 It transmits this information to the cytosol by
activating its endoribonuclease domain, which initiates an
unconventional mRNA-splicing reaction of the transcriptional
activator XBP-1 (X-box-binding protein-1).
15 The other sen-
sors of ER stress are the transmembrane proteins PERK
(RNA-dependent protein kinase-like ER kinase) and ATF-6
(activating transcription factor-6).
16 In concert, these three
pathways stimulate the expression of a set of proteins
involved in ER stress response including the luminal ER
chaperone Grp78 (glucose-regulated protein 78kDa; BiP).
17
However, when the ER function is severely impaired, the
organelle elicits cell death signals through activation of CHOP
(CCAAT/enhancer-binding protein (C/EBP) homologous pro-
tein; GADD153),
17 which in turn is described to promote
apoptosis by B-cell lymphoma gene-2 (Bcl-2)-like protein 11
(BIM) induction and Bcl-2 inhibition,
18 and/or autophagy by
LC3 (microtubule-associated protein 1 light-chain 3a) and
ATG5 (autophagy-related 5 homolog) induction.
19
Autophagy is a highly conserved cellular process in which
cytoplasmic materials, including organelles, are sequestered
into double-membrane vesicles called autophagosomes and
delivered to lysosomes for degradation or recycling. Besides
its cytoprotective role in cellular homeostasis, for example
in situations of nutrient starvation, autophagy can be a form
of programmed cell death, designated ‘type II programmed
cell death’.
20
In the present study, we have investigated the effect of the
combination between GEM and three different CB ligands,
arachidonoyl cyclopropamide (ACPA) and SR141716 (SR1)
for CB1, and GW405833 (GW) for CB2 on pancreatic
adenocarcinoma cell growth. Our results show that GEM
inducesbothCB1andCB2receptorsbyanNF-kB-dependent
mechanism. Moreover, we demonstrate that all the three
cannabinoids determine ROS production, ER stress, and
autophagiccell death,and that these effectsare potentiated by
GEM. GEM/cannabinoid treatment produces a strong syner-
gistic inhibition of pancreatic cancer cell growth in vitro,a n d
signiﬁcantly enhances the antitumoral effect of GEM in vivo.
The same treatment is ineffective on normal ﬁbroblasts and
does not determine apparent toxicity in nude mice. Altogether,
these data strongly support the development of GEM/canna-
binoid treatment in the management of pancreatic cancer.
Results
GEM/cannabinoid combined treatments synergistically
inhibited pancreatic adenocarcinoma cell proliferation. The
antiproliferative effect of the synthetic cannabinoids GW, ACPA,
and SR1 in combination with GEM was examined on six
pancreatic adenocarcinoma cell lines characterized by different
sensitivities to GEM. As reported in our previous papers,
5
CFPAC1, T3M4, and MiaPaCa2 cells are more sensitive to
GEM treatment than PaCa3, PaCa44, and Panc1 cells.
Figure 1a shows that the combined treatments signiﬁcantly
enhanced Panc1 cell growth inhibition compared with single
treatments. Similar results were obtained with all the pancreatic
adenocarcinoma cell lines assessed in this study (data not
shown). On the contrary, normal ﬁbroblasts were signiﬁcantly
less sensitive to cannabinoids and their growth was not further
inhibited by GEM addition. To analyze the trend of the inhibitory
effect over the time, we performed a time-dependent analysis of
the antiproliferative activity following a 24-h single-step treatment
with low concentrations of GEM and/or cannabinoids. Figure 1b
shows that, starting from the fourth day, only the combined
treatments were able to signiﬁcantly inhibit Panc1 cell
proliferation, with a growth ratio inhibition at the sixth day in
treated versus untreated cells of 48, 36, and 57% for GEM/GW,
GEM/ACPA, and GEM/SR1, respectively.
To evaluate whether cell growth inhibition by GEM/
cannabinoids was synergistic, we analyzed cell growth
inhibition curves by using the dedicated software CalcuSyn
(Biosoft, Ferguson, MO, USA; see ‘Materials and Methods’).
Figure 1c reports the percentages of the combination index
(CI) values encompassed between 1 and 0.3 (synergism) or
lower than 0.3 (strong synergism) for all combinations.
Although GEM-resistant cell lines showed percentages of
the overall synergism (CIo1) similar to those of GEM-
sensitive cell lines, they had a level of strong synergism
(CIo0.3) signiﬁcantly higher than that of the latter cell lines
(Supplementary Figure 1). This result suggests that canna-
binoids sensitize cancer cells to the antiproliferative effects
caused by GEM. Supplementary Table 1 shows that in the
resistant Panc1 cells, cannabinoids potentiated the effects of
GEM from 5- to 10-fold (PF). Similar results were obtained
with the other GEM-resistant cells (data not shown). On the
other hand, in agreement with data shown in Figure 1a, GEM/
cannabinoidcombinations did notdetermine anysynergism in
normal ﬁbroblasts.
GEM/cannabinoid combined treatments enhanced
intracellular ROS production. As it was previously
reported that the antiproliferative effect of GEM or
cannabinoids is mediated by oxidative stress,
5,21 we
measured ROS levels in Panc1 cells treated with
increasing concentrations of the single compounds or their
combinations. Figure 2 shows that GEM/cannabinoids were
able to signiﬁcantly enhance ROS production, induced by
single treatments, at 4h. Similar enhancement was obtained
at 16h (data not shown).
GEM induced cannabinoid receptor expression by
NF-jB-mediated mechanism. To investigate whether
GEM was able to regulate cannabinoid receptor
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Cell Death and Diseaseexpression, we performed a time-dependent analysis of the
mRNA for CB1 and CB2 receptors on Panc1 cells. As shown
in Figure 3a and Supplementary Figure 2, GEM determined
an approximately fourfold and sevenfold induction of CB1
and CB2 mRNAs, respectively. CB mRNAs induction by
GEM was transcriptionally regulated, as their increase was
completely antagonized by the addition of actinomycin D
(ActD). Similarly, both CB1 and CB2 mRNA GEM-mediated
increase was completely blocked by three NF-kB inhibitors
(BAY, pyrrolidine dithiocarbamate (PDTC), and MG132),
but not by the free radical scavenger N-acetyl-L-cysteine
(NAC; Figure 3b). IL-1, a known NF-kB inducer, stimulated
both CB1 and CB2 expression, which was antagonized by
MG132 addition. Moreover, the antiproliferative synergism
was signiﬁcantly reduced by MG132 and completely
abrogated by BAY (Figure 3c). Altogether, these data
indicate that NF-kB is involved in both ROS-independent
cannabinoid receptor induction by GEM and in the
antiproliferative synergism by GEM/cannabinoid combi-
nations, suggesting a role for CB1 and CB2 activation by
GEM in the latter effect.
GEM enhanced cannabinoid-induced ER stress. It was
previously reported that ER stress is a molecular mechanism
involved in cannabinoid antiproliferative effect.
13 To
investigate whether GEM was able to enhance the
cannabinoid-induced ER stress, we analyzed mRNA
expression of the ER stress sensors XBP-1, Grp78, and
CHOP following single or combined treatments. Figure 4
shows that all the three mRNAs were induced by GW, ACPA,
or SR1, and their levels were signiﬁcantly enhanced by the
addition of GEM, even if GEM alone was ineffective.
GEM enhanced cannabinoid-induced autophagy by a
ROS-mediated mechanism. To determine whether
apoptosis and/or cell cycle arrest were involved in the
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Figure 1 Effect of GEM and/or GW, ACPA, or SR1 on growth of pancreatic adenocarcinoma cell lines and normal ﬁbroblasts. (a) Cells were seeded in 96-well plates and
incubated overnight. The compounds were added at the concentrations of 200nM GEM, 16mM SR1 and GW, and 90mM ACPA; cells were incubated for additional 48h.
Valuesarereportedaspercentageoftreatedversusuntreatedcells,andarethemeansoftriplicatesamplesfromthreeindependentexperiments(±S.D.).Statisticalanalysis:
Po0.001, GEM versus each combination; Po0.01, each cannabinoid versus its combination with GEM in Panc1 cells, no signiﬁcance between the various treatments in
ﬁbroblasts. (b) Panc1 cells were seeded in 96-well plates and incubated overnight. The compounds were added at the following concentrations for 24h: 25nM GEM, 2mM
SR1and GW, and11.25mM ACPA.The growth ratio on the y axis was obtained by dividing theabsorbance of untreatedor treatedcell lines by the mean absorbance of each
cell line measured at time 0. Values are the means of triplicate samples from three independent experiments (±S.D.). The statistical analysis was performed for each
combinedtreatmentversuscontrol.(c)AntiproliferativesynergismbyGEM/cannabinoids.ThepercentagevalueswereobtainedbyanalyzingCI/effectcurves,asdescribedin
Materials and Methods. Statistical analysis: Po0.001, % CIo1 in all cancer cell lines versus normal ﬁbroblasts
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Cell Death and Diseaseantiproliferative synergism between GEM and cannabinoids,
we performed both annexin V-FITC/propidium iodide (PI)
assay and cell cycle analysis by ﬂow cytometry after single
or combined treatments. Figure 5a shows that GEM, but not
cannabinoids, signiﬁcantly induced apoptosis at 48h. This
effect was partially reduced by the addition of cannabinoids.
Similar results were obtained at 24h, and with PaCa44 and
T3M4 cell lines (data not shown). Figure 5b shows that GEM
increased the percentages of cells in G1 and S phases and
cannabinoids in G1 phase, and the combined treatments did
not induce a potentiation of the accumulation of cells in a
particular phase of cell cycle when compared with the changes
induced by GEM or cannabinoids alone. Altogether, these data
indicate that GEM/cannabinoid synergism is likely mediated by
neither apoptotic nor cell cycle modulation.
Recently, Salazar et al.
13 reported that tetrahydrocannabi-
nol (THC) is able to induce autophagy-mediated cell death in
human glioma cells. Therefore, we investigated whether GW,
ACPA, or SR1 also were able to induce autophagy and
whether GEM could additionally enhance this effect.
Figure 5c shows that at 24h LC3-II protein, the phospho-
ethanolaminated form of the autophagosome protein LC3-I,
was increased by single treatments with GEM or cannabi-
noids and additionally enhanced by GEM/cannabinoid com-
binations. Similar results were obtained at 48h (data not
shown). A late step in the autophagic cell death process is the
fusion of lysosomes with autophagosomes into autolyso-
somes,whichcanbedetectedbymeasuringtheiracidiﬁcation
with acridine orange staining. Interestingly, we found acridine
orange staining (characterized by a punctuation, suggesting
vacuole formation) slightly increased in GEM or cannabinoid-
treated cells and signiﬁcantly potentiated in cells treated with
GEM/cannabinoid combinations (Figure 6a). These effects
were almost completely antagonized by the addition of either
the scavenger NAC or the autophagy inhibitors CQ or 3-
methyladenine (3-MA). This observation was conﬁrmed by
FACS analysis, which shows a signiﬁcant difference in the
acidiﬁcation of the acidic vesicular organelles (AVOs) in
pancreatic cancer cells treated with GEM or cannabinoids
compared with control, and with GEM/cannabinoid combina-
tion compared with single treatments (Figure 6b). Blocking
autophagy with 3-MA or CQ resulted in a decrease in
autolysosomal acidiﬁcation, demonstrating that acidiﬁcation
induced by the different combinations was linked to the
autophagic pathway.
To ascertain whether the presence of numerous cyto-
plasmicvacuolesinGEM/combination-treatedcellswasreally
due to the induction of autophagy, the autoﬂuorescent drug
monodansylcadaverine (MDC), a selective marker for AVOs,
such as autophagic vacuoles and especially autolysosomes,
was used.
22 Figure 6c shows the quantitative evaluation of
MDCstainingperformed byFACS.We againfoundthatGEM,
SR-1,andACPAinduceda similarincreaseinAVOformation,
which was more prominent in GW-treated cells. This effect
was strongly potentiated by the GEM/cannabinoid combina-
tionsandantagonizedbytheautophagyinhibitorsCQor3-MA
or the scavenger NAC.
Figure 7a shows that either NAC, CQ, or 3-MA strongly
reduced the percentages of the antiproliferative synergism by
GEM/cannabinoids. Similar results were obtained with
PaCa44 and PaCa3 cell lines (data not shown). It is worth to
note that the NAC concentration used in these experiments
(20mM) was non-toxic by itself and was able to completely
abolish ROS induction by GEM/cannabinoids (data not
shown). Altogether, these data demonstrate that GEM
enhances cannabinoid-induced autophagy by a ROS-
mediated mechanism and that this event is required for
GEM/cannabinoid synergism. Figures 7b and c show a kinetic
analysis of the events involved in GEM/cannabinoid anti-
proliferative synergism, that is, oxidative stress, ER stress, and
autophagy. Although ROS were induced within 4h, the peak of
Grp78 and LC3-II protein expression appeared at 8 and 12/16h,
respectively, suggesting that ER stress could be a mechanism
connecting ROS induction with autophagic cell death.
GEM and cannabinoids strongly inhibited growth of
human pancreatic adenocarcinoma cells in vivo. The
effect of GEM and/or SR1 on growth inhibition of PaCa44
cells subcutaneously xenografted in nude mice was also
investigated. Figure 8a shows that the volume of tumor in
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Figure 2 Effect of GEM and/or cannabinoids on intracellular ROS production.
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Cell Death and Diseasemice treated with the combination GEMþSR1 remained
essentially unchanged during the observation time, whereas
it increased considerably in the control group and, at a lower
extent, in either GEM- or SR1-treated groups. Figure 8b
shows that mice body masses did not change during the
experiment, suggesting that the treatments did not produce
any apparent toxicity. At the end of the treatment time, the
percentages of mean tumor mass reduction relative to
control were 65, 34, or 92% in mice treated with GEM,
SR1, or GEMþSR1, respectively (Figure 8c).
Discussion
In the present study, we have demonstrated that the
combination between the standard chemotherapy agent
GEM and cannabinoids synergistically inhibited pancreatic
adenocarcinomacell growthbyaROS-dependentautophagic
cell death. We used highly speciﬁc cannabinoid ligands of
CB1 (ACPA) and CB2 (GW), and the clinically relevant CB1
ligand SR1. The latter has been described as a CB1
antagonist or inverse agonist;
23 however, at high concentra-
tion it possesses an agonist activity.
24 Our results were in
agreement with the last observation and additionally con-
ﬁrmed the dual and concentration-dependent effect of SR1 on
cell response (data not shown). SR1 counteracts obesity and
its metabolic complications regulating food intake at central
and peripheral level
25 and also exerts antitumoral activity in
some cancer types and in thyroid tumor xenografts.
26 In
contrast to SR1, to our knowledge, the antitumor activity of
ACPA and GW has never been reported before. Thus, our
results show for the ﬁrst time that GW, ACPA, or SR1, in
additiontoGEM,wereabletosynergisticallyinhibitpancreatic
adenocarcinomacell growth.Ourdata alsodemonstratedthat
low concentrations of GEM/cannabinoids added to the cells
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Cell Death and Diseasefor 24h were able to signiﬁcantly reduce pancreatic adeno-
carcinoma cell growth at least for 6 days from the beginning of
the treatment. This result may be clinically relevant, suggest-
ingthepossibilitytosetuptherapeuticprotocolsforpancreatic
cancer with low concentrations of GEM/cannabinoids that
may give reduced side effects. Our data also show that
cannabinoids were quite ineffective in normal ﬁbroblasts, and
combined treatments with GEM does not further increase cell
growth inhibition. These results are in agreement with the
observation that cannabinoid receptors are overexpressed in
cancer cells, whereas they are undetectable or expressed at
low levels in normal cells
10 and that GEM is selectively active
in cancer cells, which generally show a higher growth rate as
compared with the normal counterpart. Recently, our
research group has reported that p53
 /  pancreatic adeno-
carcinoma cell growth is strongly inhibited by ROS-inducing
compounds.
27,28 Moreover, we have demonstrated that
pancreatic adenocarcinoma cell growth inhibition by GEM is
due, at least in part, to ROS induction and that cell lines with
lower basal levels of ROS are more resistant to GEM
compared with cells with higher ROS levels.
5 Here, we report
that GEM-resistant cell lines showed a signiﬁcantly higher
synergism (CIo0.3) of cell growth inhibition by GEM/
cannabinoids compared with GEM-sensitive cell lines and
that the synergism was dependent on the increase in
intracellular ROS induced by the combinations. This mechan-
ism is supported bythe observation thatthe radical scavenger
NAC totally inhibited the synergistic antiproliferative effect
induced by GEM/cannabinoids. These ﬁndings strongly
support the idea that the increase in ROS production may
be a good strategy to overcome GEM resistance in the
therapeutic management of pancreatic cancer.
It has previously been described that cannabinoid receptor
overexpression can potentiate cannabinoid antitumor
effects.
29 Here, we report for the ﬁrst time that GEM treatment
determined CB1 and CB2 transcriptional induction, suggest-
ing its involvement in GEM/cannabinoid-induced synergism
on cell growth inhibition. The regulation of CB1 and CB2 gene
expression is currently poorly studied. Recently, Borner
et al.
30 demonstrated that STAT6 mediates the induction of
CB1 gene by IL-4 in T lymphocytes. However, it has not been
previouslydescribedthatGEMtreatmentcanactivateSTAT6,
stronglysuggestingthatCB1andCB2geneinductionbyGEM
occursbyadifferent mechanism.ASNF-kBisoneofthe most
important transcription factors induced by GEM,
31 we
analyzed the activation of CB gene by GEM in the presence
of the NF-kB inhibitors MG132, BAY, and PDTC. Both CB1
and CB2 gene induction by GEM was totally prevented by
theseinhibitors, andIL-1,a knowninducerofNF-kB,was able
to activate CB genes. Similar results were also obtained using
TNF-a (data not shown). As NF-kB induction is described to
be mediated by oxidative stress, we analyzed CB gene
induction by GEM in the presence of NAC. Our data show that
NAC failed to prevent CB induction by GEM, indicating that
GEM induces CB gene expression by a ROS-independent
mechanism. The molecular mechanism that is the basis of
NF-kB induction by GEM is still unknown and its clariﬁcation
needs additional investigations.
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Figure 4 Effect of GEM and/or cannabinoids on ER stress-related gene expression. Panc1 cells were treated with 500nM GEM and/or 40mM GW, 225mM ACPA, or
40mM SR1 for 8h. RT-PCR for XBP-1(S) and qPCR for Grp78 and CHOP were performed, as described in Materials and Methods. Densitometric analysis of XBP-1(S) was
normalized to b-actin and performed, as described in Materials and Methods. Values are the means of triplicate samples from three independent experiments (±S.D.).
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Cell Death and DiseaseThe involvement of ER stress induction in cannabinoid
antiproliferative effect has been already described.
10 Accord-
ingly, we report that the cannabinoids ACPA, GW, and SR1
activated the splicing of XBP-1 and inducted both Grp78 and
CHOP genes, which are the molecular switch inducing
apoptotic or autophagic cell death signals.
17,18 Interestingly,
we show that all the three ER stress-related genes induced by
cannabinoids, including CHOP, are additionally enhanced by
GEM, supporting their involvement in GEM/cannabinoid-
mediated antiproliferative synergism.
It has been reported that THC induces caspase activation
in pancreatic tumor cells.
10 On the other hand, our data
demonstrate that SR1, ACPA, or GW did not indeed induce
apoptotic cell death, even if they induced cell cycle arrest at
theG1phase.Thediscrepancybetweenourresultsandthose
of Carracedo et al.
10 may rely on the nature of THC, which is a
nonspeciﬁc cannabinoid receptor agonist, and requires
additional investigations to be explained. Moreover, our
results demonstrate that GEM-induced apoptosis was par-
tially, but signiﬁcantly, prevented by cannabinoids. As it has
been reported that autophagy generally precedes apopto-
sis,
32 one possible explanation may be that the stimulation of
autophagy by SR1, ACPA, or GW or by their combinations
with GEM is so elevated to inhibit the development of the
apoptotic cell death program. In agreement with this hypo-
thesis, the inhibition of autophagosome degradation by CQ is
reported to promote apoptosis in cancer cells.
33 On the other
hand,inlinewiththerecentdiscoverythatTHCactioninduces
autophagy-mediated cell death in human glioma cells,
13 we
describe that cannabinoids, as well as GEM, were able to
induce autophagy in pancreatic cancer cells and that their
combination strongly potentiated this effect. Our data also
demonstrate that CQ or 3-MA addition to GEM signiﬁcantly
reduces the antiproliferative effects of the latter, supporting
the concept that autophagy has a role in cancer cell growth
inhibition in the present experimental model. These ﬁndings
are in agreement with a recent demonstration that GEM is
able to induce autophagy and LC3-II upregulation in pancrea-
tic cancer cell lines.
34 Autophagy induction by GEM may rely
on the ability of GEM to stimulate sphingomyelinase or inhibit
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Cell Death and Diseaseneutral ceramidase, enhancing the intracellular level of
ceramide,
35 a known inducer of autophagosome formation.
The regulation of ceramide metabolism by GEM, coupled with
the observation that the cannabinoid transduction pathway
involves ceramide production,
36 which, in turn, is able
to induce oxidative stress,
37 may be at the basis of the
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Cell Death and DiseaseROS-dependent synergistic autophagic cell death by GEM/
cannabinoid combinations.
Our kinetic studies revealed that ROS induction by drug
combinations preceded the activation of the ER stress marker
Grp78, which, in turn, preceded the autophagy marker LC3-II
induction. The observation that LC3-II increase was pre-
vented by NAC and that ROS could induce ER stress
14
strongly supports the hypothesis that oxidative stress, ER
stress, and autophagic cell death were sequential events in
our experimental conditions.
For in vivo studies, we chose SR1, in addition to GEM, on
the basis of its clinical relevance.
25 Our in vivo experiments
show that intraperitoneal injections of GEMþSR1 into nude
mice bearing a subcutaneous mass of human pancreatic
Figure 6 Involvement of ROS in GEM/cannabinoid-induced autophagy. (a) Fluorescence microscopy analysis of autophagosome formation in Panc1 cells after acridine
orange staining treated with 500nM GEM and/or 40mM GW, 225mM ACPA, or 40mM SR1 in the absence or presence of 20mM NAC or 10mM CQ or 1mM 3-MA for 24h.
(b) The MFIs were calculated, as described in ‘Materials and Methods’, at FACS after trypsinization of the acridine orange-labeled cells. Values are the means of triplicate
samples from three independent experiments (±S.D.). Statistical analysis: Po0.05, control versus GEM, GW, ACPA, or SR1; Po0.001, each cannabinoid or GEM versus
their combination; and Po0.001, GEM/cannabinoids versus GEM/cannabinoidsþNAC, GEM/cannabinoidsþCQ, or GEM/cannabinoidþ3-MA. (c) Flow cytometric
analyses of autophagosomes formation (MDC incorporation) in Panc1 cells treated with 500nM GEM and/or 40mM GW, 225mM ACPA, or 40mM SR1 in the absence or
presence of20mMNACor 10mMCQ or1mM3-MAfor24h. TheMFIswerecalculated,as describedin‘MaterialsandMethods’.Valuesare themeansof threeindependent
experiments (±S.D.). Statistical analysis: Po0.01, control versus GEM, SR1, or ACPA; Po0.001, control versus GW; Po0.001, each cannabinoid or GEM versus their
combination; and Po0.001, GEM/cannabinoids versus GEM/cannabinoidsþNAC, GEM/cannabinoidsþCQ, or GEM/cannabinoidþ3-MA
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Cell Death and Diseaseadenocarcinoma cells quite completely inhibited tumor
growth. No apparent form of toxicity in vivo, such as mice
death, body mass changes, or other apparent toxicity-related
features, was observed in mice treated with GEMþSR1.
In conclusion, the results presented here provide the ﬁrst
evidence that the GEM/cannabinoid combinations exerted a
strong synergistic antiproliferative effect on pancreatic
adenocarcinoma GEM-resistant cell lines by ROS-dependent
mechanisms, whereas it is scarcely toxic toward normal cells.
Moreover, in vivo studies strongly boost the addition of
cannabinoids to GEM in designing new therapeutic strategies
for pancreatic cancer treatment.
Materials and Methods
Chemicals. GEM (Gemzar) was provided by Eli Lilly (Florence, Italy). SR141716 (N-
(piperidino-1-yl)-5-(4-chlorophenyl)-1-(2,4dichlorophenyl)-4-methyl-pyrazole-3-carboxamide);
SR1(rimonabant;Acomplia,Sanoﬁ-Aventis,Milan,Italy)waskindlyprovidedbyDr.Maurizio
Bifulco (University of Salerno, Italy); ACPA was obtained from Cayman Chemicals (Inalco,
Milan, Italy); and GW405833 hydrochloride (1-(2,3-dichlorobenzoyl)-2-methyl-3-(2-
(1-morpholine)ethyl)-5-methoxyindole; GW) from Sigma (Milan, Italy). ActD, PDTC, NAC,
E64d, chloroquine diphosphate (CQ; N
4-(7-chloro-4-quinolinyl)-N
1,N
1-dimethyl-1,4-
pentanediamine), and 3-MA were obtained from Sigma. MG132 and BAY 11-7085 (2E)-
3-94-(1,1-dimethylethyl)-phenyl-sulfonyl-2-propenenitrile) (BAY) were obtained from
Enzo Life Sciences (VinciBiochem, Florence, Italy), pepstatin A from AppliChem
(Darmstadt, Germany), and the recombinant human IL-l from PeproTech (Inalco,
Milan, Italy).
Cell culture. PaCa44, PaCa3, Panc1, CFPAC1, T3M4, and MiaPaCa2 cell
lines
38 were grown in RPMI 1640 supplemented with 2mM glutamine, 10% FBS,
and 50mg/ml gentamicin sulfate (BioWhittaker, Lonza, Bergamo, Italy), and
incubatedat 371C with 5% CO2. Normal primary ﬁbroblasts (PromoCell, PBI, Milan,
Italy) were grown in DMEM supplemented with 2mM glutamine, 10% FBS, and
50mg/ml gentamicin sulfate, and were incubated at 371C with 5% CO2.
Cell proliferation assay. Cells were plated in 96-well cell culture plates
(5 10
3 cells per well) and treated with various compounds, as indicated in the
legends to ﬁgures. At the end of the treatments, cell proliferation was evaluated by
Crystal Violet (Sigma) staining. The dye was solubilized in 1% SDS in PBS and
measured photometrically (A595nm) to determine cell viability. Three or four
independent experiments were performed for each assay condition.
Drug combination studies. The compounds were added for 48h at the
following concentration ranges: 1nM–1mM for GEM, 80nM–80mM for SR1 and
GW, and 450nM–450mM for ACPA in GEM-resistant cell lines; 0.2nM–200nM
for GEM, 100nM–100mM for SR1 and GW, and 560nM–560mM for ACPA in
GEM-sensitive cell lines. The CI was calculated by the Chou–Talalay equation,
which takes into account both the potency (IC50) and the shape of the dose–effect
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Cell Death and Diseasecurve,
39 by using the CalcuSyn software. The general equation for the classic
isobologram is given by CI¼(D)1/(Dx)1þ(D)2/(Dx)2þ((D)1 (D)2)/((Dx)1
.(Dx)2),
where(Dx)1and(Dx)2inthedenominatorsarethedoses(orconcentrations)for D1
(drug1)andD2(drug2)alonethatgivex%growthinhibition,whereas(D)1and(D)2
in the numerators are the doses of drug 1 and drug 2 in combination that also
inhibited x% cell viability (i.e., isoeffective). CIo1 and CIo0.3 indicated synergism
and strong synergism, whereas CI¼1 and CI41 indicated additive effect and
antagonism,respectively.CI/effectcurvesrepresenttheCIversusthefraction(0–1)
of cells killed by drug combination. The synergism percentage was obtained
analyzing CI/effect curve and measuring the CI values at each 0.05 fraction, that is,
5% growth inhibition, of the antiproliferative effect. Throughout all the experiments,
we obtained a linear correlation coefﬁcient (r)40.90. Drug combination studies
were performed using the following concentration ratios: [GEM]:[SR1] and
[GEM]:[GW]¼1:500 and [GEM]:[ACPA]¼1:2800 in GEM-sensitive cell lines,
whereas [GEM]:[SR1] and [GEM]:[GW]¼1:80 and [GEM]:[ACPA]¼1:450 in
GEM-resistant cell lines. These molar ratios were calculated on the basis of GEM
and cannabinoid IC50 mean values at 48h. For GEM, they correspond to 36nM for
theGEM-sensitivecelllinesand220nMfortheGEM-resistantcelllines,asreported
inourpreviousworks.
5Thethreecannabinoidswerealleffectiveinthesixcelllines,
with IC50 mean values corresponding to 18mM for SR1 and GW and 100mM for
ACPA. By inverting the molar ratios of the compounds between the two groups of
cell lines, no signiﬁcant alteration of the results was observed (data not shown),
indicating that the data obtained were not inﬂuenced by the speciﬁc experimental
condition tested.
Analysis of ROS. The non-ﬂuorescent diacetylated 20,70-dichloroﬂuorescein
(DCF-DA) probe (Sigma), which becomes highly ﬂuorescent upon oxidation, was
used to evaluate intracellular ROS production. Brieﬂy, cells were plated in 96-well
plates (5 10
3 cells per well) and, 24h later, treated with various compounds, as
indicated in the legends to ﬁgures. Then, cells were incubated with 10mM DCF-DA
for 15min at 371C, and the DCF ﬂuorescence was measured by using a multimode
plate reader (Ex 485nm and Em 535nm). Three independent experiments were
performed for each assay condition.
RNA extraction qPCR, RT-PCR, and image analysis. Total RNA was
extracted from 9 10
5 cells using TRIzol Reagent (Invitrogen, Milan, Italy), and
1mg of RNA was reverse transcribed using ﬁrst-strand cDNA synthesis. Real-time
quantiﬁcation was performed in triplicate samples by SYBR Green detection
chemistry with SYBR Green PCR Master Mix (Applied Biosystems, Invitrogen) on a
7000 Sequence Detection System. The primers used were: CB1For 50-GAGAGGT
GCCAAGGGAGCTT-30 and CB1Rev 50-GGTGCGGAAGGTGGTATCTG-30;
CB2For 50-CACAGCCTCTGTGGGTAGCC-30 and CB2Rev 50-ACGGGTGAGCA
GAGCTTTGT-30; Grp78For 50-GACGGGCAAAGATGTCAGGAA-30 and Grp78Rev
50-TCATAGTAGACCGGAACAGATCCA-30; CHOPFor 50-GCAGCCCATGAAGGA
GAAAG-30 and CHOPRev 50-CGGTCGATTTCCTGCTTGAG-30; and GAPDHFor
50-TGTGTCCGTCGTGGATCTGA-30 and GAPDHRev 50-R-GATGCCTGCTTCAC
CACCTT-30. The following cycling conditions were used: 951C for 10min, 40 cycles
at 951C for 15s, 601C for 1min, and 721C for 30s. The average of cycle threshold
of each triplicate was analyzed according to the 2
( DDCt) method. For RT-PCR,
one-tenth of the cDNA was used as a template for PCR ampliﬁcation using the following
primers and cycling conditions: b-actinFor 50-ACCAACTGGGACGACATGGAGAA-30
and b-actinRev 50-GTGGTGGTGAAGCTGTAGCC-30, 25 cycles of 941C for 60s, 551C
for 60s, and 721C for 60s; XBP-1For 50-CCTTGTAGTTGAGAACCAGG-30 and XBP-
1Rev 50-GGGGCTTGGTATATATGTGG-30,4 0c y c l e so f9 3 1C for 60s, 551Cf o r
60s, and 721C for 60s. PCR products were separated by electrophoresis through
ethidiumbromide-stained3.5%agarosegelandvisualizedbyultravioletlight.Toquantify
XBP-1 splicing, XBP-1(S) bands were scanned as digital peaks and the areas of
the peaks were calculated using the public domain NIH Image software
(http://imagej.nih.gov), normalized with b-actin mRNA expression, and reported as
fold induction relative to controls.
For ActD experiments, 2.5 10
5 Panc1 cells were seeded in 60-mm plates and
incubated overnight. Cells were pretreated with 5mg/ml ActD for 1h, then 2mM
GEM was added, and the treatments prolonged up to 16h. Total RNA extraction
and real-time PCR were performed, as above described.
Apoptosis. Thepercentageofapoptoticcellswasevaluatedbystaining3 10
5
cells with annexin V-FITC (Bender Med System, Prodotti Gianni, Milan, Italy) and
5mg/ml PI in binding buffer (10mM HEPES/NaOH (pH 7.4), 140mM NaOH, and
2.5mM CaCl2) for 10min at room temperature in the dark. The samples were
analyzedbyﬂowcytometry(FACScalibur,BectonDickinson,SanJose,CA,USA)to
determine the percentage of cells displaying annexin Vþ/PI  (early apoptosis) or
annexin Vþ/PIþ staining (late apoptosis). For each sample, we report the
percentage values corresponding to the addition of early and late apoptosis. Three
independent experiments were performed for each assay condition.
Cell cycle analysis. Cell cycle distribution was analyzed by staining 3 10
5
cells with PI. After the indicatedtreatments, cells were washed with PBS, incubated
with0.1%sodiumcitratedihydrate,0.1%TritonX-100,200mg/mlRNaseA,50mg/mlPI
(Roche Diagnostics, Milan, Italy), and analyzed using a ﬂow cytometer
(FACScalibur, Becton Dickinson). The percentage of cells in the various stages
of the cell cycle was determined using the ModFitLT software (Verity Software
House, Topsham, ME, USA). Three independent experiments were performed for
each assay condition.
Immunoblot analysis. In all, 1.2 10
6 cells were treated with the various
compounds, as indicated in the legends to ﬁgures, collected, washed in PBS, and
resuspendedinRIPAbuffer,pH8(150mMNaCl,pH8;50mMTris-HCl;1%NP-40;
0.5% Na-Doc; and 0.1% SDS), 1mM PMSF, 1mM Na3VO4, 1mM NaF, 2.5mM
EDTA, and 1  protease inhibitor cocktail (Roche Diagnostics) for 30min on ice.
The lysate was centrifuged at 14000 g for 10min at 41C, and the supernatant
was used for western blot. Protein concentration was measured with the Bradford
protein assay reagent (Pierce, Celbio, Milan, Italy) using bovine serum albumin as
standard. Fifty (for LC3-II) or thirty (for Grp78) micrograms of protein extracts were
electrophoresed through a 15% SDS-polyacrylamide gel and electroblotted onto
PVDF membranes (Millipore, Milan, Italy). Membranes were then incubated for 2h
at room temperature with blocking solution (5% low-fat milk in TBST (100mM Tris,
pH 7.5, 0.9% NaCl, and 0.1% Tween 20)) and probed overnight at 41C with the
appropriate primary antibody (1:1000 in blocking solution of LC3B (Cell Signaling,
Milan, Italy), Grp78 (Santa Cruz Biotechnology, DBA, Milan, Italy), or a-tubulin
(oncogene) antibodies). Horseradish peroxidase-conjugated IgG (1:2000 in
blocking solution, Upstate Biotechnology, Milan, Italy) was used to detect speciﬁc
proteins. Immunodetection was carried out using chemiluminescent substrates
(Amersham Pharmacia Biotech, Milan, Italy) and recorded using a Hyperﬁlm ECL
(Amersham Pharmacia Biotech). To quantify LC3-II and Grp78 expression, bands
were scanned as digital peaks and the areas of the peaks were calculated in
arbitrary units using the public domain NIH Image software (http://rsb.info.nih.gov/
nihimage/), normalized with a-tubulin expression, and reported as fold induction
relative to controls.
Labeling of autophagic vacuoles with MDC. To quantify the induction
of the autophagic process in Panc-1 cells treated with the various compounds as
indicated in the legend, MDC staining was performed, as previously described.
40
Following the treatments, cells were incubated with 50mM MDC in PBS at 371C for
15min. After incubation, cells were washed with PBS, trypsinized, and immediately
analyzed by ﬂow cytometry. All ﬂuorescences were analyzed with a FACScalibur
ﬂow cytometer (Becton Dickinson). The ﬂuorescent emissions were collected
through a 530nm band pass ﬁlter (FL1 channel). At least 10000 events were
acquired in log mode. For the quantitative evaluation of MDC, CellQuest software
(BectonDickinson)wasusedtocalculatemeanﬂuorescenceintensities(MFIs).The
MFIs were calculated by the formula (MFItreated/MFIcontrol), where MFItreated is
the ﬂuorescence intensity of cells treated with the various compounds and
MFIcontrol is the ﬂuorescence intensity of untreated and unstained cells. Values
reported in the ﬁgures are the means±S.D.s from three independent experiments.
Quantiﬁcation of AVOs with acridine orange. In acridine orange-
stained cells, the cytoplasm and nucleus are bright green and dim red, whereas
acidic compartments are bright red. The intensity of the red ﬂuorescence is
proportional to the degree of acidity. Following the treatments, as speciﬁed in the
legend, cells were incubated with acridine orange solution (1mg/ml) at 371C; after
15min in drug-free medium at 371C, they were washed with PBS, immediately
stained with 1mg/ml of acridine orange for 15min, and observed with a Nikon
Eclipse TE300 Inverted microscope (Nikon Instruments, Inc., Melville, NY, USA).
Then, cells were trypsinized and analyzed by ﬂow cytometry using FACScan
cytometer and CellQuest software, as previously described. Statistical analyses
were performed, as described above.
Invivostudies. Onthebasisofour previousexperience,we couldnotmakeuse
of Panc1 cells for in vivo studies because of their low growth rate in nude mice.
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in vitro growth inhibition studies. PaCa44 cells (2 10
6 cells/mice) were s.c.
injected into female nude mice (4 weeks of age, Harlan laboratories, Udine, Italy).
One week after cell inoculation, ﬁve randomized animals for each experimental
group received solution vehicle (PBS), 25mg/kg GEM, or/and 0.28mg/kg SR1 by
intraperitoneal injectionbiweeklyfor 4weeks.Drugdoseswerechosenon thebasis
oftheirrespectiveclinicalusefollowingUSFoodandDrugAdministrationdirectives.
Tumor volume and body mass were biweekly recorded for each animal. Animals
werekilledattheendofthe4-weekstudyperiod,andthetumorswereresectedand
weighted. Animal studies were approved by the Verona University Review Board.
Statisticalanalysis. ANOVA(posthocBonferroni)analysiswasperformedby
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). P-values o0.05,
0.01, or 0.001 were indicated as *, **, or ***, respectively.
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